Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 in acute myocardial infarction patients with moderate renal impairment
NL-OMON43079Phase 2Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing CSL112 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent renal serious adverse events and Incidence of acute kidney injury. Started Aug 2016; status: active, not recruiting.
02
Drugs
CSL112
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON43079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43079.